| Project/Area Number |
22KJ2442
|
|---|
| Project/Area Number (Other) |
22J12057 (2022)
|
|---|
| Research Category |
Grant-in-Aid for JSPS Fellows
|
| Allocation Type | Multi-year Fund (2023)
Single-year Grants (2022) |
|---|
| Section | 国内 |
|---|
| Review Section |
Basic Section 90110:Biomedical engineering-related
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
李 晋廷 九州大学, システム生命科学府, 特別研究員(DC2)
|
|---|
| Project Period (FY) |
2023-03-08 – 2024-03-31
|
| Project Status |
Completed (Fiscal Year 2023)
|
| Budget Amount *help |
¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 2023: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2022: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Keywords | allergy treatment / nanoparticle / tolerance immunity / DDS / allergy / tolerogenic nanoparticle / immunotolerance / BMDC |
|---|
| Outline of Research at the Start |
Currently, allergy with increasing concern. However, the treatment of allergies is not yet satisfying as side effects, time-consuming, questionable efficacy. Thus, this study is to design an immune therapy that utilizes nanoparticles to safely treat allergies. The nanoparticles will contain antigens and immunomodulators or targeted ligands to reduce the impact on normal cells while treatment. The study aims to efficiently induce immune tolerance to treat the disease. The innovation of this research lies in the screening best formulations, providing new possibilities for allergy treatment.
|
| Outline of Annual Research Achievements |
In the current year, my research focusing on the development of nanoparticles inducing immune tolerance for allergy treatment has made significant progress. Herein, I present an overview of my research achievements for this year:
1. Background: The number of allergy patients is on the rise. Despite immunotherapy being the only curative treatment for allergies, its high incidence of side effects and low efficacy over a treatment period of more than three years have rendered the therapy less than satisfactory. Therefore, the development of a safe and efficient treatment method has become urgent. 2. Preparation: Traditional treatment methods involve the direct administration of antigens to patients, leading to the side effects. To address this issue, I encapsulated the antigen with hydrogel nanoparticles (NP) to prevent side effects. Additionally, I modified the NP with targeting ligands to DC to enhance treatment efficiency. As results, the size of NP was adjusted to 200 nm. 3. In Vitro: NP with DC-targeting ligands significantly improved the DC uptake efficiency and increased the levels of IL-10 released by DCs, indicating their significant anti-inflammatory capabilities. 4. In Vivo: Regarding safety, NP exhibited significantly reduced binding affinity with IgE. Furthermore, repeated subcutaneous injections of NP did not induce the production of anti-drug antibodies, such as IgG and IgM. More, NP showed significant therapeutic effects on allergic model mice by decreasing IgE and the number of eosinophils.
|
